GSK is buying Rapt Therapeutics for $2.2 billion, the companies said Tuesday. Rapt stock rocketed.

That price equates to an aggregate equity value of $2.2 billion, according to GSK, who added that the upfront investment net ...

During the winter, you may struggle to feel warm no matter how much you bundle up. But some people actually break out in hives when exposed to cold, whether they’re outdoors in the winter, walking ...

It was Valentine’s Day 2018, and Jessica Tagg, then 18, had just undergone outpatient surgery for a vascular issue in her nose. She was hoping this would be her last procedure — and the Dayton high ...

The Hives have perfected what it means to be a garage rock band. Over their three-decade-spanning career, the Swedish band have hit songs like Tick Tick Boom, Come On and their breakthrough, Hate To ...

Unapproved peptide injections spark major safety concerns. Unapproved peptide injections are popular online for muscle building and anti-aging, despite health risks. Experts warn most have not been ...

Chances are, you may know a family living with food allergies. Food allergies are more prevalent than many realize, particularly among children in the United States. In 2024, an estimated 3.4 million ...

Vivid Seats is the New York Post's official ticketing partner. We may receive revenue from this partnership for sharing this content and/or when you make a purchase. Featured pricing is subject to ...

Novartis has secured FDA approval for its BTK inhibitor remibrutinib (Rhapsido) for the treatment of chronic spontaneous urticaria. Remibrutinib is the sixth BTK inhibitor to market in the US, and the ...

Doctor breaks down common side effect of using weight-loss injections - Libya’s top general killed — here’s what we know Watch: Deadly shootout bodycam video released by Bexar County Sheriff's Office ...

Kashiv Biosciences has submitted its Biologics License Applications (BLA) for ADL-018 as a biosimilar to reference product XOLAIR® (omalizumab) to the U.S. Food and Drug Administration (FDA) The ...